Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
RPRX
RPRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RPRX News
Zymeworks Secures $250 Million Royalty Financing from Royalty Pharma
Mar 02 2026
NASDAQ.COM
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Newsfilter
Zymeworks Secures $250 Million Royalty-Backed Financing
Mar 02 2026
Yahoo Finance
Teva and Medincell's NDA for Long-Acting Olanzapine Accepted by FDA
Feb 21 2026
seekingalpha
Royalty Pharma Reports Landmark 2025 Earnings with Strong Growth and Strategic Developments
Feb 11 2026
seekingalpha
Royalty Pharma Releases 2026 Financial Guidance
Feb 11 2026
seekingalpha
Royalty Pharma Set to Announce Q4 Earnings on February 11
Feb 10 2026
seekingalpha
Royalty Pharma Set for Upcoming Dividend Payment
Feb 05 2026
NASDAQ.COM
Wall Street's Latest Rating Changes Overview
Jan 30 2026
CNBC
Teva and Royalty Pharma Strike $500 Million Funding Agreement
Jan 12 2026
Benzinga
Teva Pharmaceuticals Secures $500M Deal with Royalty Pharma for TEV-408 Development
Jan 12 2026
stocktwits
Royalty Pharma (RPRX) Secures $500M Funding Agreement with Teva for TEV-'408 Development
Jan 12 2026
NASDAQ.COM
Teva (TEVA) and Royalty Pharma (RPRX) Announce $500M Funding Agreement for TEV-'408 Development
Jan 12 2026
seekingalpha
Royalty Pharma and Teva Enter $500 Million Funding Agreement for TEV-408 Development
Jan 12 2026
NASDAQ.COM
Royalty Pharma Provides Up to $500 Million to Support Teva's TEV-‘408 Development
Jan 11 2026
Globenewswire
Royalty Pharma Provides Up to $500 Million to Support Teva's TEV-‘408 Development
Jan 11 2026
Newsfilter
Show More News
